Related Experiment Videos
Abnormal expression of MDM-2 in breast carcinomas
C E Bueso-Ramos1, T Manshouri, M A Haidar
1Department of Laboratory Medicine, University of Texas M.D. Anderson Cancer Center, Houston 77030, USA.
Breast Cancer Research and Treatment
|January 1, 1996
Summary
MDM-2 oncoprotein is overexpressed in most breast cancers, affecting p53 function. This study found MDM-2 mRNA and protein alterations, particularly the p57 variant, in human breast carcinoma tissues.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- MDM-2 is a cellular oncoprotein that inhibits the tumor suppressor p53.
- MDM-2 alterations, including gene amplification and overexpression, are implicated in various cancers.
- Specific MDM-2 protein isoforms like p57 are known to exist.
Purpose of the Study:
- To investigate MDM-2 mRNA and protein expression in human breast carcinoma.
- To determine if MDM-2 overexpression occurs independently of gene amplification in breast cancer.
- To identify the predominant MDM-2 protein isoforms involved in breast carcinoma.
Main Methods:
- Quantitative analysis of MDM-2 mRNA levels in breast carcinoma and normal tissues.
- Western blot analysis to assess MDM-2 protein expression and isoforms.
- Immunohistochemistry to confirm MDM-2 and p53 protein expression.
- Analysis of MDM-2 gene amplification status.
Main Results:
- MDM-2 mRNA overexpression was observed in 73% of breast carcinomas, without gene amplification.
- A strong correlation was found between MDM-2 mRNA and protein overexpression.
- MDM-2 protein overexpression, particularly the p57 isoform, was detected in 15 out of 21 breast carcinoma samples.
Conclusions:
- MDM-2 oncoprotein expression is significantly altered at both mRNA and protein levels in primary human breast carcinomas.
- MDM-2 overexpression in breast cancer occurs independently of gene amplification.
- The MDM-2 p57 protein isoform appears to be the primary altered form in breast carcinomas, suggesting its potential role in tumorigenesis.